FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904308689> ?p ?o ?g. }

• W2904308689 endingPage "1551651" @default.
• W2904308689 startingPage "1551651" @default.
• W2904308689 abstract "Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1α), an inflammation-mediating alarmin. IL-1 receptor antagonist (IL-1Ra) is a natural molecule that blocks IL-1α activity by occupying the IL-1 receptor. The effect of endogenous IL-1Ra levels on the effectiveness of bermekimab is unknown. We investigated whether pre-treatment levels of circulating IL-1Ra, assessed by an enzyme-linked immunoassay, correlated with achievement of the primary outcome endpoint (effect on lean body mass and symptoms at week 8) in a Phase III study (2:1 randomization) of bermekimab versus placebo (each with best supportive care) in advanced colorectal cancer. Patients who responded to bermekimab in terms of achieving the primary endpoint had lower levels of IL-1Ra than non-responders (N = 204 patients; median = 843 vs. 1035 pg/ml, p=0.0092); no such relationship was observed in the placebo arm (N = 100 patients; 901 vs. 984 pg/ml, p = 0.55). Multivariate analysis corroborated that, in the bermekimab group, patients with lower baseline IL-1Ra levels were more likely to achieve the primary endpoint (odds ratio (OR) 1.7 (95% confidence interval (CI), 1.1 to 2.6), p = 0.017); in contrast, in the placebo arm, pre-treatment plasma IL-1Ra levels were not associated with outcome (OR 1.2 (95% CI 0.6 to 2.5), p = 0.57). The current findings demonstrate that, in a randomized phase III trial, patients with advanced colorectal cancer and lower levels of circulating IL-1Ra are more responsive to treatment with the IL-1α-targeting antibody bermekimab and these observations define a potential biomarker for anti-IL-1α therapy." @default.
• W2904308689 created "2018-12-22" @default.
• W2904308689 creator A5019472911 @default.
• W2904308689 creator A5027160662 @default.
• W2904308689 creator A5028234430 @default.
• W2904308689 creator A5032707613 @default.
• W2904308689 creator A5040081800 @default.
• W2904308689 creator A5053481267 @default.
• W2904308689 creator A5054550116 @default.
• W2904308689 creator A5054812831 @default.
• W2904308689 creator A5090657616 @default.
• W2904308689 date "2018-12-12" @default.
• W2904308689 modified "2023-10-06" @default.
• W2904308689 title "Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer" @default.
• W2904308689 cites W140465258 @default.
• W2904308689 cites W1653773641 @default.
• W2904308689 cites W1981000484 @default.
• W2904308689 cites W1999804784 @default.
• W2904308689 cites W2004447523 @default.
• W2904308689 cites W2025937460 @default.
• W2904308689 cites W2048459889 @default.
• W2904308689 cites W2059684646 @default.
• W2904308689 cites W2077688443 @default.
• W2904308689 cites W2097504851 @default.
• W2904308689 cites W2111074957 @default.
• W2904308689 cites W2116496447 @default.
• W2904308689 cites W2145866317 @default.
• W2904308689 cites W2150107812 @default.
• W2904308689 cites W2163312370 @default.
• W2904308689 cites W2168652736 @default.
• W2904308689 cites W2169822262 @default.
• W2904308689 cites W2401994568 @default.
• W2904308689 cites W2465860350 @default.
• W2904308689 cites W2547214152 @default.
• W2904308689 cites W2572024892 @default.
• W2904308689 cites W2750254726 @default.
• W2904308689 doi "https://doi.org/10.1080/2162402x.2018.1551651" @default.
• W2904308689 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6350690" @default.
• W2904308689 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30723583" @default.
• W2904308689 hasPublicationYear "2018" @default.
• W2904308689 type Work @default.
• W2904308689 sameAs 2904308689 @default.
• W2904308689 citedByCount "31" @default.
• W2904308689 countsByYear W29043086892019 @default.
• W2904308689 countsByYear W29043086892020 @default.
• W2904308689 countsByYear W29043086892021 @default.
• W2904308689 countsByYear W29043086892022 @default.
• W2904308689 countsByYear W29043086892023 @default.
• W2904308689 crossrefType "journal-article" @default.
• W2904308689 hasAuthorship W2904308689A5019472911 @default.
• W2904308689 hasAuthorship W2904308689A5027160662 @default.
• W2904308689 hasAuthorship W2904308689A5028234430 @default.
• W2904308689 hasAuthorship W2904308689A5032707613 @default.
• W2904308689 hasAuthorship W2904308689A5040081800 @default.
• W2904308689 hasAuthorship W2904308689A5053481267 @default.
• W2904308689 hasAuthorship W2904308689A5054550116 @default.
• W2904308689 hasAuthorship W2904308689A5054812831 @default.
• W2904308689 hasAuthorship W2904308689A5090657616 @default.
• W2904308689 hasBestOaLocation W29043086891 @default.
• W2904308689 hasConcept C121608353 @default.
• W2904308689 hasConcept C126322002 @default.
• W2904308689 hasConcept C142724271 @default.
• W2904308689 hasConcept C143998085 @default.
• W2904308689 hasConcept C149892131 @default.
• W2904308689 hasConcept C156957248 @default.
• W2904308689 hasConcept C168563851 @default.
• W2904308689 hasConcept C170493617 @default.
• W2904308689 hasConcept C203014093 @default.
• W2904308689 hasConcept C203092338 @default.
• W2904308689 hasConcept C204243189 @default.
• W2904308689 hasConcept C204787440 @default.
• W2904308689 hasConcept C27081682 @default.
• W2904308689 hasConcept C2776885963 @default.
• W2904308689 hasConcept C2778122271 @default.
• W2904308689 hasConcept C44249647 @default.
• W2904308689 hasConcept C526805850 @default.
• W2904308689 hasConcept C71924100 @default.
• W2904308689 hasConcept C90924648 @default.
• W2904308689 hasConceptScore W2904308689C121608353 @default.
• W2904308689 hasConceptScore W2904308689C126322002 @default.
• W2904308689 hasConceptScore W2904308689C142724271 @default.
• W2904308689 hasConceptScore W2904308689C143998085 @default.
• W2904308689 hasConceptScore W2904308689C149892131 @default.
• W2904308689 hasConceptScore W2904308689C156957248 @default.
• W2904308689 hasConceptScore W2904308689C168563851 @default.
• W2904308689 hasConceptScore W2904308689C170493617 @default.
• W2904308689 hasConceptScore W2904308689C203014093 @default.
• W2904308689 hasConceptScore W2904308689C203092338 @default.
• W2904308689 hasConceptScore W2904308689C204243189 @default.
• W2904308689 hasConceptScore W2904308689C204787440 @default.
• W2904308689 hasConceptScore W2904308689C27081682 @default.
• W2904308689 hasConceptScore W2904308689C2776885963 @default.
• W2904308689 hasConceptScore W2904308689C2778122271 @default.
• W2904308689 hasConceptScore W2904308689C44249647 @default.
• W2904308689 hasConceptScore W2904308689C526805850 @default.
• W2904308689 hasConceptScore W2904308689C71924100 @default.
• W2904308689 hasConceptScore W2904308689C90924648 @default.
• W2904308689 hasFunder F4320332161 @default.

• next